Business Context and Reporting Period
Company: Halozyme Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date: December 8, 2005
Event: Entry into a Material Definitive Agreement (Second Amendment to an Exclusive Distribution Agreement).
Key Financial Metrics
The filing text does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. This report focuses exclusively on the terms of a new contractual agreement.
Material Changes and Agreement Terms
On December 8, 2005, Halozyme entered into a Second Amendment with Baxter Healthcare Corporation regarding the distribution of Halozyme's Hylenex product. Key terms include:
- Exclusive Distribution: Baxter will market and sell Hylenex exclusively in the European Union (EU) and selected other European countries (collectively, the "Additional Territory"), pending regulatory approvals.
- Regulatory Costs: Halozyme and Baxter will equally share costs associated with obtaining regulatory approvals in the Additional Territory.
- Sales and Marketing Costs: Baxter will pay annualized sales and marketing costs up to an agreed-upon amount. Costs exceeding this amount will be split equally between the parties, subject to mutual agreement on the additional amount.
- Profit Sharing: Halozyme will receive 50% of the gross profit from Hylenex sales in the Additional Territory.
Guidance, Outlook, and Risks
Outlook: The agreement expands the commercial reach of Hylenex into European markets, contingent upon regulatory approvals.
Risks/Contingencies: The distribution rights and associated revenue streams are pending applicable regulatory approvals in the Additional Territory. The full text of the agreement is not included in this filing and will be filed in the next annual report on Form 10-KSB.
Investor Verification Checklist
- Verify the status of regulatory approvals for Hylenex in the EU and Additional Territory.
- Review the specific "agreed upon amount" for annualized sales and marketing costs once disclosed in future filings.
- Monitor the upcoming Form 10-KSB for the complete text of the Second Amendment.
- Assess the impact of shared regulatory costs on Halozyme's cash flow.